[A24-117] Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V
Last updated 04.03.2025
Project no.:
A24-117
Commission:
Commission awarded on 29.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Children 1 to 11 years of age, weighing at least 15 kg, with eosinophilic oesophagitis who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-117